{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:54:29Z","timestamp":1761897269767,"version":"3.44.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011946","name":"Abbott Diabetes Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011946","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.diabres.2020.108131","type":"journal-article","created":{"date-parts":[[2020,3,29]],"date-time":"2020-03-29T09:53:33Z","timestamp":1585475613000},"page":"108131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes"],"prefix":"10.1016","volume":"162","author":[{"given":"Thorsten","family":"Siegmund","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Ampudia-Blasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2020.108131_b0005","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 9th ed. In. Brussels, Belgium; 2019."},{"issue":"15","key":"10.1016\/j.diabres.2020.108131_b0010","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"New Engl J Med"},{"issue":"10146","key":"10.1016\/j.diabres.2020.108131_b0015","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(18)31506-X","article-title":"Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study","volume":"392","author":"Rawshani","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.diabres.2020.108131_b0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/dia.2018.0384","article-title":"State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016\u20132018","volume":"21","author":"Foster","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.diabres.2020.108131_b0025","doi-asserted-by":"crossref","DOI":"10.1177\/2042018819830867","article-title":"Patient and disease characteristics of adult patients with type 1 diabetes in Germany: an analysis of the DPV and DIVE databases","volume":"10","author":"van Mark","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.diabres.2020.108131_b0030","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2337\/dc18-1444","article-title":"Validation of time in range as an outcome measure for diabetes clinical trials","volume":"42","author":"Beck","year":"2019","journal-title":"Diab Care"},{"key":"10.1016\/j.diabres.2020.108131_b0035","unstructured":"First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes [press release]. European Medicines Agency, 01\/02\/2019; EMA\/CHMP\/46542\/2019; 2019."},{"issue":"10166","key":"10.1016\/j.diabres.2020.108131_b0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"12","key":"10.1016\/j.diabres.2020.108131_b0045","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diab Care"},{"issue":"9","key":"10.1016\/j.diabres.2020.108131_b0050","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diab Care"},{"key":"10.1016\/j.diabres.2020.108131_b0055","unstructured":"European Medicines Agency. EPAR Dapagliflozin. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/forxiga [updated 28\/08\/2019. accessed 20\/11\/2019]."},{"issue":"Supplement_1","key":"10.1016\/j.diabres.2020.108131_b0060","doi-asserted-by":"crossref","DOI":"10.1210\/js.2019-SAT-LB025","article-title":"SAT-LB025 Analysis of Benefit\/Risk in the Subgroup of Patients with BMI of >=27 Kg\/m2 in the Dapagliflozin DEPICT-1 and -2 Trials in Type 1 Diabetes","volume":"3","author":"Mathieu","year":"2019","journal-title":"J Endocr Soc"},{"issue":"6","key":"10.1016\/j.diabres.2020.108131_b0065","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","article-title":"International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors","volume":"42","author":"Danne","year":"2019","journal-title":"Diab Care"},{"issue":"10","key":"10.1016\/j.diabres.2020.108131_b0070","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1007\/s00125-018-4671-6","article-title":"SGLT inhibitor adjunct therapy in type 1 diabetes","volume":"61","author":"McCrimmon","year":"2018","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.diabres.2020.108131_b0075","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diab Care"},{"key":"10.1016\/j.diabres.2020.108131_b0080","article-title":"Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes","author":"Hiyoshi","year":"2017","journal-title":"J Biomed Res"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720303818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720303818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:13:12Z","timestamp":1759173192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822720303818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":16,"alternative-id":["S0168822720303818"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108131","relation":{},"ISSN":["0168-8227"],"issn-type":[{"type":"print","value":"0168-8227"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108131"}}